checkAd
    Startseite > Aktien > GSK > Nachrichten
    GSK Aktie
    37,80
     
    EUR
    -8,70 %
    -3,60 EUR
    Letzter Kurs 16:51:51 Tradegate
    37,20
     
    EUR
    140 STK
    Geldkurs 17:39:33
    37,40
     
    EUR
    140 STK
    Briefkurs 17:39:33
    ISIN: US37733W2044 · WKN: A3DMHS · SYM: GS70 · Großbritannien

    Neueste Nachrichten

    Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
    14:10 Uhr · Business Wire (engl.) · GSK
    Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
    02.06.24 · Business Wire (engl.) · GSK
    Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
    16.03.24 · Business Wire (engl.) · GSK
    GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
    07.03.24 · Business Wire (engl.) · GSK
    GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
    06.02.24 · Business Wire (engl.) · GSK
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 02.02.2024
    02.02.24 · wO Chartvergleich · China Mobile
    Elegen und GSK unterzeichnen Kooperations- und Lizenzvereinbarung zur Weiterentwicklung der zellfreien DNA-Produktionstechnologie von Elegen
    24.01.24 · Business Wire (dt.) · GSK
    Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
    24.01.24 · Business Wire (engl.) · GSK
    GSK Enters Agreement to Acquire Aiolos Bio
    09.01.24 · Business Wire (engl.) · GSK
    GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
    12.12.23 · Business Wire (engl.) · GSK
    GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
    13.11.23 · Business Wire (engl.) · GSK
    New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
    25.10.23 · Business Wire (engl.) · GSK